Share Price and Basic Stock Data
Last Updated: January 22, 2026, 7:32 pm
| PEG Ratio | 3.10 |
|---|
Analyst Insight & Comprehensive Analysis
AI Stock Ranker – Real-Time Fundamental Strength Score
Business Overview and Revenue Trends
Alkosign Ltd operates in a sector that is not explicitly defined in the provided data. The company’s revenue trajectory reflects a significant growth trend, with reported sales rising from ₹4.03 Cr in September 2021 to ₹21.25 Cr by September 2023. This represents a remarkable compound annual growth rate (CAGR) of approximately 107.7% over this two-year period. The company’s most recent quarterly sales reported for March 2024 stood at ₹14.43 Cr, while projections for September 2024 indicate a further rise to ₹27.90 Cr. This consistent upward movement in revenue underscores an effective business strategy and market positioning. Annual sales figures also echo this trend, where sales increased from ₹10.16 Cr in March 2022 to ₹35.69 Cr in March 2024. The trailing twelve months (TTM) sales reached ₹49.97 Cr, indicating robust operational momentum.
Profitability and Efficiency Metrics
Alkosign Ltd’s profitability metrics exhibit volatility but show potential for improvement. The company’s operating profit margin (OPM) recorded a significant peak of 40.47% in September 2023, followed by a decline to 7.40% by September 2025. This fluctuation indicates the company’s capacity to enhance operational efficiency but also highlights potential challenges in maintaining margin stability. The net profit for September 2023 stood at ₹5.80 Cr, reflecting a substantial recovery from previous losses, with a net profit margin of 27.25%. However, net profit margins dropped to 0.39 Cr by September 2025. The interest coverage ratio (ICR) of 7.47x demonstrates a strong ability to meet interest obligations, indicating financial health. The return on equity (ROE) at 12% and return on capital employed (ROCE) at 12.8% suggest that the company utilizes its capital effectively, although these figures remain below some industry benchmarks.
Balance Sheet Strength and Financial Ratios
Alkosign Ltd’s balance sheet reflects a mixed financial position. The total assets rose to ₹54.74 Cr as of September 2025, with total liabilities amounting to ₹54.74 Cr, resulting in a debt-to-equity ratio of 0.38x, suggesting a relatively low level of financial leverage. Borrowings decreased from ₹20.47 Cr in March 2020 to ₹13.41 Cr by September 2025, indicating prudent debt management. Reserves increased from ₹0.66 Cr in March 2020 to ₹22.59 Cr by September 2025, providing a cushion for future growth and potential investments. The price-to-book value (P/BV) ratio stands at 2.09x, which is relatively high compared to typical sector ranges, suggesting that investors are willing to pay a premium for the company’s equity based on its growth prospects. The current ratio of 2.54x indicates that the company is well-positioned to cover its short-term liabilities, further enhancing its financial stability.
Shareholding Pattern and Investor Confidence
The shareholding pattern of Alkosign Ltd reflects a balanced distribution among various stakeholders. As of September 2025, promoters hold 43.35% of the equity, which shows a slight increase from 40.32% in March 2024, indicating growing confidence from the company’s management in its future prospects. Foreign institutional investors (FIIs) and domestic institutional investors (DIIs) account for 9.94% and 3.35% of the equity, respectively, suggesting a modest interest from institutional investors. The public holds 43.36%, indicating a strong retail presence. Over the past few years, the number of shareholders has fluctuated, with 615 shareholders reported in September 2025, down from 757 in September 2024. This decline may raise concerns about retail investor confidence, which could impact liquidity and market sentiment.
Outlook, Risks, and Final Insight
Alkosign Ltd’s outlook appears cautiously optimistic, bolstered by robust revenue growth and an improving balance sheet. However, risks persist, particularly regarding profitability volatility and dependency on market conditions. The significant fluctuations in OPM and net profit margins suggest that while the company has growth potential, it may face challenges in sustaining profitability during adverse market conditions. Additionally, the decreasing number of shareholders could indicate waning retail interest, which may affect stock liquidity. To navigate these risks, Alkosign Ltd needs to focus on enhancing operational efficiency and maintaining a stable profit margin. The company may also benefit from exploring new market opportunities to diversify its revenue streams. If successful, this could position Alkosign Ltd favorably in the evolving market landscape, potentially unlocking additional value for shareholders.
Source: Getaka Fundamental Analysis | Generated using proprietary financial data.
Competitors
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| Gujarat Metallic Coal & Coke Ltd | 5.94 Cr. | 30.0 | / | 77.6 | 0.00 % | 0.37 % | 2.00 % | 100 | |
| Gensol Engineering Ltd | 88.5 Cr. | 23.0 | 776/20.5 | 0.86 | 155 | 0.00 % | 14.3 % | 22.4 % | 10.0 |
| Fusion Micro Finance Ltd | 2,842 Cr. | 177 | 212/124 | 118 | 0.00 % | 2.96 % | 54.5 % | 10.0 | |
| Five X Tradecom Ltd | 0.99 Cr. | 0.48 | / | 9.35 | 0.00 % | 0.00 % | 0.00 % | 10.0 | |
| East West Holdings Ltd | 37.0 Cr. | 2.90 | 7.99/2.70 | 4.93 | 0.00 % | 6.98 % | 0.86 % | 2.00 | |
| Industry Average | 6,497.09 Cr | 199.06 | 261.41 | 219.28 | 0.27% | 11.73% | 22.92% | 9.00 |
Quarterly Result
| Metric | Sep 2021 | Mar 2022 | Sep 2022 | Mar 2023 | Sep 2023 | Mar 2024 | Sep 2024 | Mar 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|
| Sales | 4.03 | 6.13 | 9.11 | 12.27 | 21.25 | 14.43 | 27.90 | 23.63 | 26.34 |
| Expenses | 3.38 | 5.91 | 8.18 | 10.38 | 12.65 | 18.52 | 23.06 | 20.67 | 24.39 |
| Operating Profit | 0.65 | 0.22 | 0.93 | 1.89 | 8.60 | -4.09 | 4.84 | 2.96 | 1.95 |
| OPM % | 16.13% | 3.59% | 10.21% | 15.40% | 40.47% | -28.34% | 17.35% | 12.53% | 7.40% |
| Other Income | 0.00 | 0.06 | 0.03 | 0.22 | 0.04 | 0.24 | 0.15 | 0.16 | 0.16 |
| Interest | 0.40 | 0.44 | 0.64 | 0.87 | 0.45 | 1.22 | 0.51 | 0.57 | 0.60 |
| Depreciation | 0.69 | 0.97 | 0.94 | 1.00 | 1.20 | 1.25 | 1.17 | 1.25 | 1.11 |
| Profit before tax | -0.44 | -1.13 | -0.62 | 0.24 | 6.99 | -6.32 | 3.31 | 1.30 | 0.40 |
| Tax % | -6.82% | -15.04% | 1.61% | 25.00% | 17.02% | -20.73% | 0.00% | 65.38% | 0.00% |
| Net Profit | -0.41 | -0.96 | -0.63 | 0.18 | 5.80 | -5.02 | 3.31 | 0.46 | 0.39 |
| EPS in Rs | -1.17 | -0.77 | 0.22 | 5.37 | -4.65 | 3.06 | 0.43 | 0.36 |
Last Updated: December 28, 2025, 6:01 am
Below is a detailed analysis of the quarterly data for Alkosign Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:
- For Sales, as of Sep 2025, the value is 26.34 Cr.. The value appears strong and on an upward trend. It has increased from 23.63 Cr. (Mar 2025) to 26.34 Cr., marking an increase of 2.71 Cr..
- For Expenses, as of Sep 2025, the value is 24.39 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 20.67 Cr. (Mar 2025) to 24.39 Cr., marking an increase of 3.72 Cr..
- For Operating Profit, as of Sep 2025, the value is 1.95 Cr.. The value appears to be declining and may need further review. It has decreased from 2.96 Cr. (Mar 2025) to 1.95 Cr., marking a decrease of 1.01 Cr..
- For OPM %, as of Sep 2025, the value is 7.40%. The value appears to be declining and may need further review. It has decreased from 12.53% (Mar 2025) to 7.40%, marking a decrease of 5.13%.
- For Other Income, as of Sep 2025, the value is 0.16 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 0.16 Cr..
- For Interest, as of Sep 2025, the value is 0.60 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 0.57 Cr. (Mar 2025) to 0.60 Cr., marking an increase of 0.03 Cr..
- For Depreciation, as of Sep 2025, the value is 1.11 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 1.25 Cr. (Mar 2025) to 1.11 Cr., marking a decrease of 0.14 Cr..
- For Profit before tax, as of Sep 2025, the value is 0.40 Cr.. The value appears to be declining and may need further review. It has decreased from 1.30 Cr. (Mar 2025) to 0.40 Cr., marking a decrease of 0.90 Cr..
- For Tax %, as of Sep 2025, the value is 0.00%. The value appears to be improving (decreasing) as expected. It has decreased from 65.38% (Mar 2025) to 0.00%, marking a decrease of 65.38%.
- For Net Profit, as of Sep 2025, the value is 0.39 Cr.. The value appears to be declining and may need further review. It has decreased from 0.46 Cr. (Mar 2025) to 0.39 Cr., marking a decrease of 0.07 Cr..
- For EPS in Rs, as of Sep 2025, the value is 0.36. The value appears to be declining and may need further review. It has decreased from 0.43 (Mar 2025) to 0.36, marking a decrease of 0.07.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: December 15, 2025, 4:16 am
| Metric | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|
| Sales | 13.24 | 13.24 | 10.16 | 21.38 | 35.69 | 51.53 | 49.97 |
| Expenses | 11.85 | 11.85 | 9.28 | 18.55 | 31.18 | 43.72 | 45.06 |
| Operating Profit | 1.39 | 1.39 | 0.88 | 2.83 | 4.51 | 7.81 | 4.91 |
| OPM % | 10.50% | 10.50% | 8.66% | 13.24% | 12.64% | 15.16% | 9.83% |
| Other Income | 0.03 | 0.03 | 0.05 | 0.25 | 0.28 | 0.32 | 0.32 |
| Interest | 0.31 | 0.31 | 0.84 | 1.51 | 1.67 | 1.09 | 1.17 |
| Depreciation | 0.20 | 0.20 | 1.66 | 1.95 | 2.45 | 2.42 | 2.36 |
| Profit before tax | 0.91 | 0.91 | -1.57 | -0.38 | 0.67 | 4.62 | 1.70 |
| Tax % | 27.47% | 27.47% | -12.74% | 21.05% | -16.42% | 18.40% | |
| Net Profit | 0.66 | 0.66 | -1.38 | -0.46 | 0.78 | 3.77 | 0.85 |
| EPS in Rs | -1.68 | -0.56 | 0.72 | 3.49 | 0.79 | ||
| Dividend Payout % | 0.00% | 0.00% | 0.00% | 0.00% | 9.23% | 0.00% |
YoY Net Profit Growth
| Year | 2020-2021 | 2021-2022 | 2022-2023 | 2023-2024 | 2024-2025 |
|---|---|---|---|---|---|
| YoY Net Profit Growth (%) | 0.00% | -309.09% | 66.67% | 269.57% | 383.33% |
| Change in YoY Net Profit Growth (%) | 0.00% | -309.09% | 375.76% | 202.90% | 113.77% |
Alkosign Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 5 years from 2020-2021 to 2024-2025.
Growth
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | 31% |
| 3 Years: | 72% |
| TTM: | 44% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | 42% |
| 3 Years: | 68% |
| TTM: | 409% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | 22% |
| 1 Year: | -9% |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | 5% |
| 3 Years: | 6% |
| Last Year: | 12% |
Last Updated: September 5, 2025, 2:11 pm
Balance Sheet
Last Updated: December 4, 2025, 2:20 am
| Month | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|
| Equity Capital | 0.01 | 0.01 | 5.45 | 5.45 | 7.20 | 7.20 | 10.79 |
| Reserves | 0.66 | 0.66 | 7.17 | 6.71 | 22.02 | 25.79 | 22.59 |
| Borrowings | 20.47 | 20.47 | 16.03 | 20.40 | 13.85 | 12.55 | 13.41 |
| Other Liabilities | 2.52 | 2.37 | 0.88 | 2.23 | 6.76 | 5.51 | 7.95 |
| Total Liabilities | 23.66 | 23.51 | 29.53 | 34.79 | 49.83 | 51.05 | 54.74 |
| Fixed Assets | 1.56 | 1.56 | 15.95 | 18.35 | 16.93 | 16.31 | 16.94 |
| CWIP | 14.28 | 14.28 | 0.00 | 0.00 | 0.61 | 0.54 | 0.00 |
| Investments | 0.10 | 0.10 | 0.10 | 0.10 | 0.10 | 0.00 | 0.00 |
| Other Assets | 7.72 | 7.57 | 13.48 | 16.34 | 32.19 | 34.20 | 37.80 |
| Total Assets | 23.66 | 23.51 | 29.53 | 34.79 | 49.83 | 51.05 | 54.74 |
Below is a detailed analysis of the balance sheet data for Alkosign Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:
- For Equity Capital, as of Sep 2025, the value is 10.79 Cr.. The value appears strong and on an upward trend. It has increased from 7.20 Cr. (Mar 2025) to 10.79 Cr., marking an increase of 3.59 Cr..
- For Reserves, as of Sep 2025, the value is 22.59 Cr.. The value appears to be declining and may need further review. It has decreased from 25.79 Cr. (Mar 2025) to 22.59 Cr., marking a decrease of 3.20 Cr..
- For Borrowings, as of Sep 2025, the value is 13.41 Cr.. The value appears to be increasing, which may not be favorable. Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has increased from 12.55 Cr. (Mar 2025) to 13.41 Cr., marking an increase of 0.86 Cr..
- For Other Liabilities, as of Sep 2025, the value is 7.95 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 5.51 Cr. (Mar 2025) to 7.95 Cr., marking an increase of 2.44 Cr..
- For Total Liabilities, as of Sep 2025, the value is 54.74 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 51.05 Cr. (Mar 2025) to 54.74 Cr., marking an increase of 3.69 Cr..
- For Fixed Assets, as of Sep 2025, the value is 16.94 Cr.. The value appears strong and on an upward trend. It has increased from 16.31 Cr. (Mar 2025) to 16.94 Cr., marking an increase of 0.63 Cr..
- For CWIP, as of Sep 2025, the value is 0.00 Cr.. The value appears to be declining and may need further review. It has decreased from 0.54 Cr. (Mar 2025) to 0.00 Cr., marking a decrease of 0.54 Cr..
- For Investments, as of Sep 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 0.00 Cr..
- For Other Assets, as of Sep 2025, the value is 37.80 Cr.. The value appears strong and on an upward trend. It has increased from 34.20 Cr. (Mar 2025) to 37.80 Cr., marking an increase of 3.60 Cr..
- For Total Assets, as of Sep 2025, the value is 54.74 Cr.. The value appears strong and on an upward trend. It has increased from 51.05 Cr. (Mar 2025) to 54.74 Cr., marking an increase of 3.69 Cr..
Notably, the Reserves (22.59 Cr.) exceed the Borrowings (13.41 Cr.), indicating a solid financial buffer.
Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.
Cash Flow
| Month | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|
Free Cash Flow
| Month | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|
| Free Cash Flow | -19.08 | -19.08 | -15.15 | -17.57 | -9.34 | -4.74 |
Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)
Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.
Financial Efficiency Indicators
| Month | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|
| Debtor Days | 137.56 | 137.56 | 83.71 | 47.12 | 57.58 | 84.57 |
| Inventory Days | 115.21 | 115.21 | 202.07 | 267.67 | 278.07 | 203.40 |
| Days Payable | 98.90 | 98.90 | 31.43 | 32.54 | 97.88 | 47.61 |
| Cash Conversion Cycle | 153.88 | 153.88 | 254.34 | 282.25 | 237.77 | 240.36 |
| Working Capital Days | -164.03 | -163.20 | -105.26 | -14.00 | 109.33 | 120.13 |
| ROCE % | 5.77% | -2.89% | 3.69% | 6.06% | 12.78% |
This stock is not held by any mutual fund.
Key Financial Ratios
| Month | Mar 25 | Mar 24 |
|---|---|---|
| FaceValue | 10.00 | 10.00 |
| Basic EPS (Rs.) | 5.24 | 1.22 |
| Diluted EPS (Rs.) | 5.24 | 1.22 |
| Cash EPS (Rs.) | 8.60 | 4.50 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | 45.84 | 40.61 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | 45.84 | 40.61 |
| Revenue From Operations / Share (Rs.) | 71.62 | 49.60 |
| PBDIT / Share (Rs.) | 11.29 | 6.66 |
| PBIT / Share (Rs.) | 7.93 | 3.25 |
| PBT / Share (Rs.) | 6.42 | 0.92 |
| Net Profit / Share (Rs.) | 5.24 | 1.09 |
| NP After MI And SOA / Share (Rs.) | 5.24 | 1.09 |
| PBDIT Margin (%) | 15.76 | 13.41 |
| PBIT Margin (%) | 11.07 | 6.54 |
| PBT Margin (%) | 8.96 | 1.86 |
| Net Profit Margin (%) | 7.31 | 2.19 |
| NP After MI And SOA Margin (%) | 7.31 | 2.19 |
| Return on Networth / Equity (%) | 11.42 | 2.68 |
| Return on Capital Employeed (%) | 15.05 | 6.57 |
| Return On Assets (%) | 7.38 | 1.57 |
| Long Term Debt / Equity (X) | 0.14 | 0.21 |
| Total Debt / Equity (X) | 0.38 | 0.47 |
| Asset Turnover Ratio (%) | 1.02 | 0.00 |
| Current Ratio (X) | 2.54 | 2.21 |
| Quick Ratio (X) | 1.24 | 1.07 |
| Inventory Turnover Ratio (X) | 3.09 | 0.00 |
| Interest Coverage Ratio (X) | 7.47 | 2.87 |
| Interest Coverage Ratio (Post Tax) (X) | 4.46 | 1.47 |
| Enterprise Value (Cr.) | 78.34 | 130.32 |
| EV / Net Operating Revenue (X) | 1.52 | 3.65 |
| EV / EBITDA (X) | 9.64 | 27.21 |
| MarketCap / Net Operating Revenue (X) | 1.34 | 3.45 |
| Price / BV (X) | 2.09 | 4.21 |
| Price / Net Operating Revenue (X) | 1.34 | 3.45 |
| EarningsYield | 0.05 | 0.01 |
After reviewing the key financial ratios for Alkosign Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 25, the value is 10.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 10.00.
- For Basic EPS (Rs.), as of Mar 25, the value is 5.24. This value is within the healthy range. It has increased from 1.22 (Mar 24) to 5.24, marking an increase of 4.02.
- For Diluted EPS (Rs.), as of Mar 25, the value is 5.24. This value is within the healthy range. It has increased from 1.22 (Mar 24) to 5.24, marking an increase of 4.02.
- For Cash EPS (Rs.), as of Mar 25, the value is 8.60. This value is within the healthy range. It has increased from 4.50 (Mar 24) to 8.60, marking an increase of 4.10.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 45.84. It has increased from 40.61 (Mar 24) to 45.84, marking an increase of 5.23.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 45.84. It has increased from 40.61 (Mar 24) to 45.84, marking an increase of 5.23.
- For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 71.62. It has increased from 49.60 (Mar 24) to 71.62, marking an increase of 22.02.
- For PBDIT / Share (Rs.), as of Mar 25, the value is 11.29. This value is within the healthy range. It has increased from 6.66 (Mar 24) to 11.29, marking an increase of 4.63.
- For PBIT / Share (Rs.), as of Mar 25, the value is 7.93. This value is within the healthy range. It has increased from 3.25 (Mar 24) to 7.93, marking an increase of 4.68.
- For PBT / Share (Rs.), as of Mar 25, the value is 6.42. This value is within the healthy range. It has increased from 0.92 (Mar 24) to 6.42, marking an increase of 5.50.
- For Net Profit / Share (Rs.), as of Mar 25, the value is 5.24. This value is within the healthy range. It has increased from 1.09 (Mar 24) to 5.24, marking an increase of 4.15.
- For NP After MI And SOA / Share (Rs.), as of Mar 25, the value is 5.24. This value is within the healthy range. It has increased from 1.09 (Mar 24) to 5.24, marking an increase of 4.15.
- For PBDIT Margin (%), as of Mar 25, the value is 15.76. This value is within the healthy range. It has increased from 13.41 (Mar 24) to 15.76, marking an increase of 2.35.
- For PBIT Margin (%), as of Mar 25, the value is 11.07. This value is within the healthy range. It has increased from 6.54 (Mar 24) to 11.07, marking an increase of 4.53.
- For PBT Margin (%), as of Mar 25, the value is 8.96. This value is below the healthy minimum of 10. It has increased from 1.86 (Mar 24) to 8.96, marking an increase of 7.10.
- For Net Profit Margin (%), as of Mar 25, the value is 7.31. This value is within the healthy range. It has increased from 2.19 (Mar 24) to 7.31, marking an increase of 5.12.
- For NP After MI And SOA Margin (%), as of Mar 25, the value is 7.31. This value is below the healthy minimum of 8. It has increased from 2.19 (Mar 24) to 7.31, marking an increase of 5.12.
- For Return on Networth / Equity (%), as of Mar 25, the value is 11.42. This value is below the healthy minimum of 15. It has increased from 2.68 (Mar 24) to 11.42, marking an increase of 8.74.
- For Return on Capital Employeed (%), as of Mar 25, the value is 15.05. This value is within the healthy range. It has increased from 6.57 (Mar 24) to 15.05, marking an increase of 8.48.
- For Return On Assets (%), as of Mar 25, the value is 7.38. This value is within the healthy range. It has increased from 1.57 (Mar 24) to 7.38, marking an increase of 5.81.
- For Long Term Debt / Equity (X), as of Mar 25, the value is 0.14. This value is below the healthy minimum of 0.2. It has decreased from 0.21 (Mar 24) to 0.14, marking a decrease of 0.07.
- For Total Debt / Equity (X), as of Mar 25, the value is 0.38. This value is within the healthy range. It has decreased from 0.47 (Mar 24) to 0.38, marking a decrease of 0.09.
- For Asset Turnover Ratio (%), as of Mar 25, the value is 1.02. It has increased from 0.00 (Mar 24) to 1.02, marking an increase of 1.02.
- For Current Ratio (X), as of Mar 25, the value is 2.54. This value is within the healthy range. It has increased from 2.21 (Mar 24) to 2.54, marking an increase of 0.33.
- For Quick Ratio (X), as of Mar 25, the value is 1.24. This value is within the healthy range. It has increased from 1.07 (Mar 24) to 1.24, marking an increase of 0.17.
- For Inventory Turnover Ratio (X), as of Mar 25, the value is 3.09. This value is below the healthy minimum of 4. It has increased from 0.00 (Mar 24) to 3.09, marking an increase of 3.09.
- For Interest Coverage Ratio (X), as of Mar 25, the value is 7.47. This value is within the healthy range. It has increased from 2.87 (Mar 24) to 7.47, marking an increase of 4.60.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 4.46. This value is within the healthy range. It has increased from 1.47 (Mar 24) to 4.46, marking an increase of 2.99.
- For Enterprise Value (Cr.), as of Mar 25, the value is 78.34. It has decreased from 130.32 (Mar 24) to 78.34, marking a decrease of 51.98.
- For EV / Net Operating Revenue (X), as of Mar 25, the value is 1.52. This value is within the healthy range. It has decreased from 3.65 (Mar 24) to 1.52, marking a decrease of 2.13.
- For EV / EBITDA (X), as of Mar 25, the value is 9.64. This value is within the healthy range. It has decreased from 27.21 (Mar 24) to 9.64, marking a decrease of 17.57.
- For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 1.34. This value is within the healthy range. It has decreased from 3.45 (Mar 24) to 1.34, marking a decrease of 2.11.
- For Price / BV (X), as of Mar 25, the value is 2.09. This value is within the healthy range. It has decreased from 4.21 (Mar 24) to 2.09, marking a decrease of 2.12.
- For Price / Net Operating Revenue (X), as of Mar 25, the value is 1.34. This value is within the healthy range. It has decreased from 3.45 (Mar 24) to 1.34, marking a decrease of 2.11.
- For EarningsYield, as of Mar 25, the value is 0.05. This value is below the healthy minimum of 5. It has increased from 0.01 (Mar 24) to 0.05, marking an increase of 0.04.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
| Strength | Weakness |
|---|---|
|
|
Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Alkosign Ltd:
- Net Profit Margin: 7.31%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: 15.05% (Industry Average ROCE: 11.73%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: 11.42% (Industry Average ROE: 22.92%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): 4.46
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 1.24
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 87.6 (Industry average Stock P/E: 261.41)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: 0.38
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: 7.31%
About the Company - Qualitative Analysis
| INDUSTRY | ADDRESS | CONTACT |
|---|---|---|
| Printing/Publishing/Stationery | Plot No. 12-A, MIDC, NR Mother Dairy, Thane Maharashtra 421311 | Contact not found |
| Management | |
|---|---|
| Name | Position Held |
| Mr. Samir Narendra Shah | Chairman & Managing Director |
| Mr. Shrenik Kamlesh Shah | Whole Time Director |
| Mr. Akshay Narendra Shah | Non Executive Director |
| Ms. Zeenal Shrenik Shah | Non Executive Director |
| Mr. Parshva Vinaykant Doshi | Ind. Non-Executive Director |
| Mr. Yogesh Ramgopal Gupta | Ind. Non-Executive Director |
| Ms. Seema Ashim Jhaveri | Ind. Non-Executive Director |
FAQ
What is the intrinsic value of Alkosign Ltd?
Alkosign Ltd's intrinsic value (as of 26 January 2026) is ₹339.93 which is 392.65% higher the current market price of ₹69.00, indicating undervalued. Calculated using the PE ratio method, this valuation considers the company's ₹74.5 Cr. market cap, FY2025-2026 high/low of ₹85.5/46.0, reserves of ₹22.59 Cr, and liabilities of ₹54.74 Cr.
What is the Market Cap of Alkosign Ltd?
The Market Cap of Alkosign Ltd is 74.5 Cr..
What is the current Stock Price of Alkosign Ltd as on 26 January 2026?
The current stock price of Alkosign Ltd as on 26 January 2026 is ₹69.0.
What is the High / Low of Alkosign Ltd stocks in FY 2025-2026?
In FY 2025-2026, the High / Low of Alkosign Ltd stocks is ₹85.5/46.0.
What is the Stock P/E of Alkosign Ltd?
The Stock P/E of Alkosign Ltd is 87.6.
What is the Book Value of Alkosign Ltd?
The Book Value of Alkosign Ltd is 30.9.
What is the Dividend Yield of Alkosign Ltd?
The Dividend Yield of Alkosign Ltd is 0.00 %.
What is the ROCE of Alkosign Ltd?
The ROCE of Alkosign Ltd is 12.8 %.
What is the ROE of Alkosign Ltd?
The ROE of Alkosign Ltd is 12.0 %.
What is the Face Value of Alkosign Ltd?
The Face Value of Alkosign Ltd is 10.0.